TY - JOUR
T1 - Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
AU - Blair, John E.A.
AU - Khan, Sadiya
AU - Konstam, Marvin A.
AU - Swedberg, Karl
AU - Zannad, Faiez
AU - Burnett, John C.
AU - Grinfeld, Liliana
AU - Maggioni, Aldo P.
AU - Udelson, James E.
AU - Zimmer, Christopher A.
AU - Ouyang, John
AU - Chen, Chien Feng
AU - Gheorghiade, Mihai
N1 - Funding Information:
Conflict of interest: J.B. is a consultant for Debiopharm. K.S. has received research grants from AstraZeneca, Servier, and Amgen; is a consultant for Cytokinetics, Servier, and Novartis; and has received honoraria from AstraZeneca, Otsuka, Amgen, and Servier. M.K. has received research grants and contracts from, is a consultant for, and has received honoraria from Otsuka. F.Z. has received research grants from Bayer; is a consultant for Servier and Johnson & Johnson; and has received honoraria from AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, Abbott, sanofi-aventis, and Otsuka. J.B. has received research grants from the National Institutes of Health, Microbia, and Theravance; is a consultant for Abbott, Bayer, Otsuka, Wyeth, and Astellas; and has received honoraria from Scios, Otsuka, and Orqis. L.G. has received research grants from GlaxoSmithKline, Otsuka, Amgen, and Bristol; is a consultant for Cordis; and has received honoraria from GlaxoSmithKline, Otsuka, Cordis, Amgen, and Bristol. A.M. has received research grants from the National Institutes of Health, Italian Ministry of Health, Astra-Zeneca, Novartis, Pfizer, Takeda, Società Prodotti Antibiotici, Sigma Tau, sanofi-aventis, and GiennePharma; is a consultant for Novartis and Daiichi Sankyo; and has received honoraria from AstraZeneca, Novartis, Takeda, Società Prodotti Antibiotici, Sigma Tau, sanofi-aventis, Servier, and Otsuka. J.U. has been a consultant for and received research grants and honoraria from Otsuka. C. Zimmer, J.O., and C.C. are employees of Otsuka. M.G. has received research grants from the National Institutes of Health, Otsuka, Sigma Tau, Merck, and Scios Inc; is a consultant for Debbio Pharm, Errekappa Terapeutici, Glaxo-SmithKline, Protein Design Laboratories, and Medtronic; and has received honoraria from Abbott, AstraZeneca, GlaxoSmithKline, Medtronic, Otsuka, Protein Design Laboratories, Scios Inc, and Sigma Tau.
PY - 2009/7
Y1 - 2009/7
N2 - Aims increases in body weight (BW) are important determinants for hospitalization in ambulatory patients with heart failure (HF), but have not yet been explored in patients hospitalized for worsening HF. We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial.Methods and resultsThe EVEREST trial randomized 4133 patients hospitalized for worsening HF and low ejection fraction (≤40) to tolvaptan, a vasopressin antagonist, or placebo. Following discharge, BW was assessed at 1, 4, and 8 weeks, and every 8 weeks thereafter. A time-dependent Cox proportional Hazard model explored the relationship between change in BW at 60, 120, and 180 days from discharge and the risks of HF hospitalization, cardiovascular (CV) hospitalization, and all-cause mortality. For subjects re-hospitalized for heart failure at 60, 120, and 180 days after discharge, mean BW increase prior to the event was 1.96, 2.07, and 1.97 kg, respectively, compared with 0.74, 0.90, and 1.04 kg in patients without re-hospitalization (P < 0.001 all groups). A similar pattern was observed with CV hospitalization. However, increases in BW were not predictive of all-cause mortality.ConclusionIncreases in BW after hospitalization for worsening HF was predictive of repeat hospitalization events, but not mortality in the post-discharge period.
AB - Aims increases in body weight (BW) are important determinants for hospitalization in ambulatory patients with heart failure (HF), but have not yet been explored in patients hospitalized for worsening HF. We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial.Methods and resultsThe EVEREST trial randomized 4133 patients hospitalized for worsening HF and low ejection fraction (≤40) to tolvaptan, a vasopressin antagonist, or placebo. Following discharge, BW was assessed at 1, 4, and 8 weeks, and every 8 weeks thereafter. A time-dependent Cox proportional Hazard model explored the relationship between change in BW at 60, 120, and 180 days from discharge and the risks of HF hospitalization, cardiovascular (CV) hospitalization, and all-cause mortality. For subjects re-hospitalized for heart failure at 60, 120, and 180 days after discharge, mean BW increase prior to the event was 1.96, 2.07, and 1.97 kg, respectively, compared with 0.74, 0.90, and 1.04 kg in patients without re-hospitalization (P < 0.001 all groups). A similar pattern was observed with CV hospitalization. However, increases in BW were not predictive of all-cause mortality.ConclusionIncreases in BW after hospitalization for worsening HF was predictive of repeat hospitalization events, but not mortality in the post-discharge period.
KW - Body weight
KW - Heart failure hospitalizations
KW - Outcomes
UR - http://www.scopus.com/inward/record.url?scp=66949129107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66949129107&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehp144
DO - 10.1093/eurheartj/ehp144
M3 - Article
C2 - 19411662
AN - SCOPUS:66949129107
VL - 30
SP - 1666
EP - 1673
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 13
ER -